US2019328708A1PendingUtilityA1
Method for administration
Est. expiryMar 19, 2032(~5.6 yrs left)· nominal 20-yr term from priority
A61P 35/00A61K 9/146A61K 31/40A61K 31/401A61K 2121/00
61
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
There is provided a new dosage regimen for Compound A which maximizes anti-tumor activity while maintaining acceptable toxicity levels.
Claims
exact text as granted — not AI-modifiedWhat is claimed:
1 . A method of treating a patient suffering from cancer, comprising administering to said patient a pharmaceutical composition containing as an active ingredient Compound A in an amount from about 800 mg/day to about 3000 mg/day, daily, for up to about 7 days, followed by a rest period of up to about 21 days, said administration starting on the first day of a 28 day treatment cycle.
2 . A method of treating a patient suffering from cancer, comprising administering to said patient a pharmaceutical composition containing as an active ingredient Compound A in an amount from about 800 mg/day to about 3000 mg/day, daily, for up to about 5 days, followed by a rest period of up to about 23 days, said administration starting on the first day of a 28 day treatment cycle.
3 . The method of claim 2 wherein Compound A is administered in an amount from about 1000 mg/day to about 2500 mg/day.
4 . The method of claim 3 wherein Compound A is administered in an amount of from about 1250 mg/day to about 1800 mg/day.
5 . The method of claim 1 wherein the treatment cycle being repeated every 28 days for up to about 12 cycles.
6 . The method of claim 1 wherein Compound A is administered twice daily in equal doses.
7 . The method of claim 1 wherein the cancer is colorectal cancer.
8 . The method of claim 1 wherein the cancer is prostate cancer.
9 . The method of claim 1 wherein the cancer is lung cancer.
10 . The method of claim 1 wherein the cancer is kidney cancer.
11 . The method of claim 1 wherein the cancer is breast cancer.Join the waitlist — get patent alerts
Track US2019328708A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.